Eli Lilly’s Zepbound, on top of older drug, reduced psoriatic arthritis symptoms
statnews.com••business
Key Points:
- Eli Lilly reported that combining its weight loss drug Zepbound with the immunology therapy Taltz improved outcomes for obese patients with psoriatic arthritis (PsA) more than Taltz alone.
- The GLP-1 drug Zepbound, previously effective for obesity and sleep apnea, shows potential benefits for treating PsA, an autoimmune condition causing joint pain.
- Despite promising results, it remains uncertain whether this combination will significantly change prescribing habits, given the high demand for Zepbound primarily for its weight loss benefits.
